eli lilly glp-1 news ad war leads to lawsuit by Novo Nordisk, claiming misleads Eli Lilly scales back naperiglipron

MT-II reduces adiposity through both the induction of caloric deficit and inhibiting the retention of subcutaneous and visceral fatty tissue

To advance GLP-1 receptor agonist-specific nutrition protocols, the researchers called for large-scale studies to understand nutrient intake in GLP-1 users before, during and after treatment

[44] Semaglutide remains contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

GLP-2 supports intestinal mucosal growth and gut barrier function

Additionally, altered DSIP responses in major depression and suicidal patients suggest its role in addressing dysregulated stress in mood disorders (5)